Generics makers expected to ramp up Viagra copies; Elder gets OK for API;

> Drug company Elder Pharmaceuticals has received certificate of suitability from European regulators for Diosmin API, a drug used to treat vascular diseases. Item

> The World Health Organization has expressed interest in seeing SMS text technology used to fight counterfeits in some countries. Item

> Indian generics maker Cipla is slashing by 63% the price on another cancer drug, this time targeting Roche's ($RHHBY) lung cancer drug Tarceva. Story

> India-based Sun Pharmaceutical is buying U.S. dermatology drugmaker DUSA Pharmaceuticals for about $230 million. Story

> Agere Pharmaceuticals says it upgraded its manufacturing capabilities so it can now provide spray drying. Item

And Finally... Pfizer ($PFE) expects generics makers to start churning out copycat versions of Viagra after a court in Canada sided with Teva Pharmaceutical Industries ($TEVA) and invalidated Pfizer's patent there. Story

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.